Primary Prevention of Cardiovascular Disease for People Living with Human Immunodeficiency Virus
Copyright © 2023 Elsevier Inc. All rights reserved..
People living with HIV (PLWH) have a risk of cardiovascular disease (CVD) that is 1.5 to 2 times higher than the general population owing to traditional risk factors, HIV-mediated factors like chronic inflammation and immune dysfunction, and exposure to antiretroviral therapy. Currently available CVD risk estimation calculators tend to underestimate risk in PLWH but can be useful when an individual's HIV history is considered. Improving modifiable risks is the primary intervention for reducing CVD risk in PLWH. Statin therapy is important for specific individuals, but attention should be given to drug interactions with antiretroviral agents used to treat HIV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
The Nursing clinics of North America - 59(2024), 2 vom: 26. Apr., Seite 219-233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fox, Christopher B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-HIV Agents |
|---|
| Anmerkungen: |
Date Completed 26.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cnur.2023.12.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371595363 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371595363 | ||
| 003 | DE-627 | ||
| 005 | 20240427232909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240427s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cnur.2023.12.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1390.xml |
| 035 | |a (DE-627)NLM371595363 | ||
| 035 | |a (NLM)38670691 | ||
| 035 | |a (PII)S0029-6465(23)00119-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fox, Christopher B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Primary Prevention of Cardiovascular Disease for People Living with Human Immunodeficiency Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a People living with HIV (PLWH) have a risk of cardiovascular disease (CVD) that is 1.5 to 2 times higher than the general population owing to traditional risk factors, HIV-mediated factors like chronic inflammation and immune dysfunction, and exposure to antiretroviral therapy. Currently available CVD risk estimation calculators tend to underestimate risk in PLWH but can be useful when an individual's HIV history is considered. Improving modifiable risks is the primary intervention for reducing CVD risk in PLWH. Statin therapy is important for specific individuals, but attention should be given to drug interactions with antiretroviral agents used to treat HIV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Human immunodeficiency virus | |
| 650 | 4 | |a Primary prevention | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 700 | 1 | |a Butler, Kristine |e verfasserin |4 aut | |
| 700 | 1 | |a Flynn, Devon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Nursing clinics of North America |d 1966 |g 59(2024), 2 vom: 26. Apr., Seite 219-233 |w (DE-627)NLM000043672 |x 1558-1357 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2024 |g number:2 |g day:26 |g month:04 |g pages:219-233 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cnur.2023.12.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2024 |e 2 |b 26 |c 04 |h 219-233 | ||